SCHEMBL6428694

SCHEMBL6428694

C=C[N]N1CCCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269561 0.75 BRD4 (0.35)
SCHEMBL15733100 0.74 BRD4 (0.46)
SCHEMBL103451 0.72
SCHEMBL14267986 0.70
SCHEMBL19112993 0.68
SCHEMBL15049110 0.67 BRD4 (0.39)
SCHEMBL10872294 0.66 KDM4E (0.40)
SCHEMBL104286 0.65
SCHEMBL5473091 0.65 BRD4 (0.42)
SCHEMBL10869 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110741019-A Construction body for specifically recognizing glypican 3 and application thereof 优瑞科生物技术公司 2020-01-31 CN disclosed
US-6884879-B1 Anti-VEGF antibodies GENENTECH, INC. (US) 2005-04-26 US disclosed
US-20040006018-A1 Cardiotrophin and uses therefor GENENTECH, INC. 2004-01-08 US disclosed
EP-0918794-B1 USES FOR WNT POLYPEPTIDES GENENTECH INC (US) 2003-10-15 EP disclosed
US-6492331-B1 NL8 tie ligands homologues GENENTECH, INC. 2002-12-10 US disclosed
EP-0956041-A1 USE OF IGF-I FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE AND RELATED INDICATIONS DALHOUSIE UNIVERSITY (CA) 1999-11-17 EP disclosed
WO-1998011913-A1 USE OF IGF-I FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE AND RELATED INDICATIONS DALHOUSIE UNIVERSITY (CA) 1998-03-26 WO disclosed